PCV90 - The cost–effectiveness of rivaroxaban compared to enoxaparin plus adjusted-dose warfarin for the treatment of deep venous thrombosis (DVT) in Turkey

E Parali,O Ozdemir,K Bozkurt,M Demir,B Ince,H Kultursay,G Ongen,Z Ongen,C Deger,B Marmarali,M.O Ozel,F Sumer,E Tuna,Z.S Yilmaz

doi:10.1016/j.jval.2013.03.1492

PCV90 - The cost–effectiveness of rivaroxaban compared to enoxaparin plus adjusted-dose warfarin for the treatment of deep venous thrombosis (DVT) in Turkey

E Parali, O Ozdemir + Show 12 more

Open Access

https://doi.org/10.1016/j.jval.2013.03.1492

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: May 1, 2013
License type: publisher-specific-oa

Affiliation: Istanbul University-Cerrahpaşa, Trakya University

#Treatment Of Deep Venous Thrombosis #Deep Venous Thrombosis + Show 4 more

Abstract
Full-Text PDF
Similar Papers

Abstract

PCV90 - The cost–effectiveness of rivaroxaban compared to enoxaparin plus adjusted-dose warfarin for the treatment of deep venous thrombosis (DVT) in Turkey

Full Text